Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Haebel

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|November 11, 2005
Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruziMónica I Esteva, Katja Kettler, Cristina Maidana, et al.
Molecular Metabolism|November 10, 2022
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacyTina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism|July 6, 2025
Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutideRobert Augustin, Anouk Oldenburger, Tamara Baader-Pagler, et al.
Molecular Metabolism|February 4, 2026
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulationTina Zimmermann, Katherin Bleymehl, Peter Haebel, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|November 11, 2005
Benzophenone-based farnesyltransferase inhibitors with high activity against Trypanosoma cruziMónica I Esteva, Katja Kettler, Cristina Maidana, et al.
Molecular Metabolism|November 10, 2022
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacyTina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism|July 6, 2025
Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutideRobert Augustin, Anouk Oldenburger, Tamara Baader-Pagler, et al.
Molecular Metabolism|February 4, 2026
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulationTina Zimmermann, Katherin Bleymehl, Peter Haebel, et al.
Pageof 2